Management of Asymptomatic Candiduria and Bladder Leukoplakia in Renal‑Transplant Recipients

General Recommendations

The Infectious Diseases Society of America (IDSA) recommends that, in a renal‑transplant patient with incidentally discovered bladder leukoplakia and turbid urine but no symptoms, the ureteral JJ stent should be removed and empirical antifungal therapy should not be started; tacrolimus levels should be maintained within the standard therapeutic range of 5–15 ng/mL. 1
According to IDSA guidance, asymptomatic candiduria does not require antifungal treatment in most transplant recipients, except for high‑risk groups such as neutropenic patients, very‑low‑birth‑weight neonates (<1500 g), or individuals who will undergo urologic manipulation. 2
Removal of any indwelling urinary device (e.g., JJ stent) is the most critical intervention because urinary catheters are the principal predisposing factor for candiduria. 3
Bladder leukoplakia observed on cystoscopy may indicate Candida colonisation, but in the absence of fever, dysuria, or worsening renal function it does not constitute an indication for antifungal therapy. 4

Indications for Antifungal Therapy

Antifungal treatment should be considered only when the patient develops symptomatic infection (e.g., fever, flank pain, or decline in graft function) or when a planned urologic procedure is imminent.

Antifungal Regimens (per IDSA)

Clinical scenario	Recommended regimen	Notes
Cystitis caused by fluconazole‑susceptible Candida	Fluconazole 200 mg PO daily (≈3 mg/kg) for 14 days	Standard oral therapy for uncomplicated cystitis. [5]
Pyelonephritis caused by fluconazole‑susceptible Candida	Fluconazole 200–400 mg PO daily (3–6 mg/kg) for 14 days	Dose adjusted to severity; higher end for renal involvement. [6]
Infection with fluconazole‑resistant species (C. glabrata, C. krusei)	Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days ± flucytosine 25 mg/kg PO q6h	Combination used for severe or resistant infections. [5]
Fluconazole‑resistant C. glabrata	Flucytosine monotherapy 25 mg/kg PO q6h for 14 days	Consider when amphotericin B is contraindicated. [6]

Diagnostic Work‑up

Obtain a urine culture with species identification and susceptibility testing before initiating any antifungal agent, because fluconazole susceptibility varies widely among Candida species. 7
Amphotericin B has no clinically significant interaction with tacrolimus, but its potential additive nephrotoxicity mandates close monitoring of renal function during therapy. 1

Drug‑Interaction Considerations with Tacrolimus

Azole antifungals (fluconazole, itraconazole, posaconazole, voriconazole) markedly increase tacrolimus concentrations by inhibiting CYP3A4; dose reductions of 50–75 % are advised when these agents are started, with trough levels checked every 2–3 days. (Citation omitted because source was “ignore ref”)

Proposed Management Algorithm (IDSA‑based)

Management of Candiduria (Evidence‑Based Recommendations)

General Principles

Most patients with candiduria should not receive antifungal therapy; the priority is prompt removal of urinary catheters and correction of predisposing factors, reserving antifungals only for high‑risk groups or symptomatic infection. 9

Asymptomatic Candiduria – When NOT to Treat

In asymptomatic patients, antifungal treatment does not improve mortality, reduce recurrence, or shorten hospital stay; therefore it is generally unnecessary. 9
Immediate removal or replacement of indwelling urinary catheters is the single most critical intervention and often resolves candiduria without medication. 9, 10

High‑Risk Groups Requiring Antifungal Therapy (Even If Asymptomatic)

Neutropenic patients – treat as systemic candidemia with systemic antifungal therapy. 9
Very low‑birth‑weight infants (< 1500 g) – treat as systemic candidemia with systemic antifungal therapy. 9
Patients scheduled for urologic procedures – require prophylactic antifungal therapy. 9

Prophylaxis for Urologic Procedures

Administer fluconazole 400 mg (≈6 mg/kg) daily or amphotericin B deoxycholate 0.3–0.6 mg/kg daily, beginning several days before the procedure and continuing several days after. 9

Symptomatic Candiduria – Lower Urinary Tract (Cystitis)

Fluconazole‑susceptible species (e.g., C. albicans)

Give fluconazole 200 mg (≈3 mg/kg) orally once daily for 14 days and remove any indwelling catheter. 9, 10

Fluconazole‑resistant C. glabrata

Use amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days or flucytosine 25 mg/kg orally four times daily for 7–10 days; bladder irrigation with amphotericin B (50 mg/L sterile water daily for 5 days) may be added as adjunctive therapy. 9, 10

C. krusei

Treat with amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days. 9, 10, 11

Symptomatic Candiduria – Upper Urinary Tract (Pyelonephritis)

Fluconazole‑susceptible species

Provide fluconazole 200–400 mg (3–6 mg/kg) orally daily for 14 days; the higher 400 mg dose is recommended for more severe infections. 9, 12, 11

Fluconazole‑resistant C. glabrata

Administer amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days with or without flucytosine 25 mg/kg orally four times daily; if amphotericin B is contraindicated, flucytosine monotherapy 25 mg/kg four times daily for 14 days may be used. 9, 12, 11

C. krusei

Use amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days. 12, 11

Additional Therapeutic Interventions for Pyelonephritis

Eliminate any urinary tract obstruction (e.g., relieve obstruction, ensure adequate drainage) – essential for treatment success. 12, 11
Remove or replace nephrostomy tubes or stents when feasible. 12, 11

Species‑Specific Considerations

C. glabrata is frequently fluconazole‑resistant; treatment generally requires amphotericin B or flucytosine. 9
C. krusei is intrinsically fluconazole‑resistant and always requires amphotericin B therapy. 9, 10

Management of Urinary Candidiasis in Symptomatic Patients and High‑Risk Groups

1. Initial Critical Steps

Immediate removal of any indwelling urinary catheter (within 48–72 h) is the single most important intervention and often resolves candiduria without antifungal therapy – recommended by the Infectious Diseases Society of America (IDSA) [13][14].
Obtain a urine culture with species identification and antifungal susceptibility testing before starting therapy (implicit in IDSA guidance).

2. When to Treat / When Not to Treat

2.1. Asymptomatic Candiduria – No Treatment Required

In immunocompetent patients without symptoms or planned urologic procedures, antifungal therapy does not improve mortality, reduce recurrence, or shorten hospital stay – IDSA recommendation [13][14].

2.2. High‑Risk Asymptomatic Patients – Treat Promptly

Neutropenic patients and very low‑birth‑weight infants (<1500 g) should be treated as systemic candidemia – IDSA guidance [13][14].
Patients undergoing urologic procedures require prophylaxis with either fluconazole 400 mg (≈6 mg/kg) daily or amphotericin B deoxycholate 0.3–0.6 mg/kg daily, started several days before and continued several days after the procedure – IDSA recommendation [13][14].

2.3. Symptomatic Infections – Require Therapy

Fever, dysuria, flank pain, suprapubic pain, or declining renal function indicate true infection that must be treated (clinical context supported by IDSA).

3. Treatment Regimens

3.1. Symptomatic Cystitis (Lower Urinary Tract)

Pathogen / Susceptibility	Recommended Regimen (14 days)	Comments
Fluconazole‑susceptible C. albicans or susceptible C. glabrata	Fluconazole 200 mg (≈3 mg/kg) PO once daily plus catheter removal	IDSA [13][14]
Fluconazole‑resistant C. glabrata	• Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days or • Flucytosine 25 mg/kg PO q6h for 7–10 days	IDSA [13][14]
	Adjunct: Amphotericin B bladder irrigation 50 mg/L sterile water daily for 5 days (optional)	IDSA [13][14]
C. krusei (intrinsically fluconazole‑resistant)	Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days	IDSA [13][14]

3.2. Symptomatic Pyelonephritis (Upper Urinary Tract)

Pathogen / Susceptibility	Recommended Regimen (14 days)	Comments
Fluconazole‑susceptible species	Fluconazole 200–400 mg (≈3–6 mg/kg) PO daily; use 400 mg for severe disease	IDSA [13][14]
Fluconazole‑resistant C. glabrata	• Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days with or without flucytosine 25 mg/kg PO q6h or • If amphotericin contraindicated, flucytosine monotherapy 25 mg/kg PO q6h for 14 days	IDSA [13][14]
C. krusei	Amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days	IDSA [13][14]

3.3. Additional Interventions for Pyelonephritis

Relieve any urinary tract obstruction (e.g., drainage, stent exchange) – essential for treatment success – IDSA [13][14].
Remove or replace nephrostomy tubes or ureteral stents when feasible – IDSA [13][14].

4. Pharmacologic Considerations

Fluconazole is the drug of choice for urinary candidiasis because it attains high urinary concentrations in active form, is available both orally and intravenously, and has an excellent safety profile – IDSA 13.
Flucytosine provides excellent urinary concentrations but requires monitoring for bone‑marrow toxicity and should not be used as prolonged monotherapy due to rapid resistance development – IDSA 13.
Amphotericin B deoxycholate is the alternative when fluconazole cannot be used (resistance, allergy, or treatment failure) – IDSA guidance (implicit).

5. Common Pitfalls to Avoid

Do not treat asymptomatic candiduria reflexively; overtreatment does not improve outcomes – IDSA [13][14].
Do not assume all Candida species are fluconazole‑susceptible; C. krusei is intrinsically resistant and C. glabrata frequently shows resistance – IDSA 13.
Do not use echinocandins for urinary candidiasis because they achieve negligible urinary concentrations and have documented failures (guideline‑based caution).
Never omit catheter removal; antifungal therapy without catheter removal has a high failure rate – IDSA [13][14].
Do not delay therapy in neutropenic patients or neonates; immediate systemic antifungal treatment is required even if candiduria is asymptomatic – IDSA [13][14].

6. Special Situations

6.1. Fungal Balls (Bezoars)

Surgical intervention or percutaneous drainage is required in addition to antifungal therapy – IDSA 14.
If a nephrostomy tube is present, irrigation with amphotericin B (25–50 mg in 200–500 mL sterile water) can be employed – IDSA 14.
Antifungal therapy alone is insufficient without mechanical removal or drainage – IDSA 14.

Epidemiology of Asymptomatic Candiduria in ICU Patients

Prevalence and Clinical Significance

In intensive‑care unit (ICU) patients, approximately 25 % of candiduria cases are asymptomatic and represent benign colonization rather than true infection, indicating that routine antifungal treatment is unnecessary in this subgroup. 15

Guideline Recommendations for Candiduria Management

General Principles

In most patients with yeast detected on urinalysis, antifungal therapy is unnecessary; the priority is prompt removal of any indwelling urinary catheter and correction of predisposing factors, reserving antifungal treatment for high‑risk groups (neutropenic patients, very low‑birth‑weight neonates, or those undergoing urologic procedures)【16】【17】.

Management of Asymptomatic Candiduria

Removing or replacing an indwelling urinary catheter within 48–72 hours resolves candiduria in the majority of asymptomatic cases without the need for medication【16】【17】.
Addressing modifiable risk factors such as hyperglycemia, immunosuppression, and recent broad‑spectrum antibiotic exposure further supports spontaneous clearance【16】【17】.
Clinical observation after catheter removal is sufficient, as candiduria often resolves spontaneously【16】【18】.

High‑Risk Populations Requiring Antifungal Therapy (Even When Asymptomatic)

Neutropenic patients – treat as systemic candidemia with an echinocandin or a lipid formulation of amphotericin B【19】【16】.
Very low‑birth‑weight infants (<1500 g) – treat as disseminated candidiasis with amphotericin B deoxycholate 1 mg/kg daily or fluconazole 12 mg/kg daily【19】【16】.
Patients scheduled for urologic procedures – provide prophylaxis with fluconazole 400 mg (≈6 mg/kg) daily or amphotericin B deoxycholate 0.3–0.6 mg/kg daily, beginning several days before the procedure and continuing for several days after【16】【17】.

Treatment of Symptomatic Lower Urinary Tract Infection (Cystitis)

Fluconazole‑susceptible species (e.g., C. albicans, susceptible C. glabrata): fluconazole 200 mg (≈3 mg/kg) orally once daily for 14 days plus immediate catheter removal【16】【17】【18】.
Fluconazole‑resistant C. glabrata: either amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days or flucytosine 25 mg/kg orally four times daily for 7–10 days【16】【17】【18】.
Adjunctive bladder irrigation with amphotericin B solution (50 mg/L sterile water daily for 5 days) may be added, but it is associated with a high relapse rate【16】【17】【18】.
Intrinsic fluconazole‑resistant C. krusei: amphotericin B deoxycholate 0.3–0.6 mg/kg IV daily for 1–7 days【16】【17】【18】.

Treatment of Symptomatic Upper Urinary Tract Infection (Pyelonephritis)

Fluconazole‑susceptible species: fluconazole 200–400 mg (≈3–6 mg/kg) orally daily for 14 days; the higher 400 mg dose is recommended for severe infection【16】【17】【18】.
Relief of any urinary tract obstruction (e.g., drainage, stent exchange) is essential for therapeutic success【16】【17】【18】.
Fluconazole‑resistant C. glabrata: amphotericin B deoxycholate 0.5–0.7 mg/kg IV daily with or without flucytosine 25 mg/kg orally four times daily for 14 days【16】【17】【18】.
If amphotericin B is contraindicated, flucytosine monotherapy 25 mg/kg orally four times daily for 14 days is an alternative【16】【17】【18】.
Intrinsic fluconazole‑resistant C. krusei: amphotericin B deoxycholate 0.5–0.7 mg/kg IV daily for 14 days【16】【17】【18】.

Diagnostic Work‑up Prior to Antifungal Initiation

Obtain repeat urinalysis and urine culture with species identification and antifungal susceptibility testing, as C. glabrata and C. krusei frequently exhibit fluconazole resistance【16】【20】.
In high‑risk or critically ill patients, evaluate for disseminated candidiasis (blood cultures, fundoscopic examination, hepatic/splenic imaging)【19】.

Critical Pitfalls to Avoid

Reflex treatment of asymptomatic candiduria does not improve outcomes and promotes antifungal resistance【16】【17】.
Omitting catheter removal leads to a high failure rate of antifungal therapy【16】【17】.
Echinocandins should be avoided for urinary candidiasis because they achieve negligible urinary concentrations and have documented treatment failures【18】.
Assuming all Candida species are fluconazole‑susceptible is unsafe; C. krusei is intrinsically resistant and C. glabrata shows fluconazole resistance in ~20 % of isolates【16】【18】.
Delay of systemic antifungal therapy in neutropenic patients or very low‑birth‑weight neonates is contraindicated, even when candiduria is asymptomatic【16】【17】.

Pharmacologic Rationale

Fluconazole is the preferred agent because it is highly water‑soluble, excreted unchanged in the urine, and reliably attains urinary concentrations exceeding the MIC for most Candida isolates【16】【17】【18】.
Flucytosine achieves excellent urinary levels but requires monitoring for bone‑marrow toxicity and should not be used as prolonged monotherapy due to rapid emergence of resistance【16】【17】【18】.
Amphotericin B deoxycholate serves as the alternative when fluconazole cannot be used (e.g., resistance, allergy, treatment failure)【16】【17】【18】.
Lipid formulations of amphotericin B are not recommended as first‑line therapy for urinary candidiasis because of presumed low renal tissue penetration and documented treatment failures【18】.